Table 3 Targeted therapies for OA

Senolytics

Quercetin and Dasatinib

Selectively induce apoptosis in senescent cells while not affecting proliferating cells

[120,121,122]

USP7 inhibitors

Activate the apoptotic program after the stabilization of p53 to kill senescent cells

[123]

ABT263 (Navitoclax)

Eliminate senescent cells, reduce the expression of inflammatory cytokines and promote the maintenance of chondrogenic phenotypes in vitro

[111]

Senomorphics

Nutlin-3a

Increase p53 levels and attenuate the secretory phenotype of senescent cells

[124, 125]

Canakinumab

Inhibition of IL-1β expression delays the progression of OA

[126]

CL82198

Reduce the severity of OA by inhibiting chondrocyte death

[127]